Microbot Medical Inc MBOT.OQ MBOT.O is expected to show no change in quarterly revenue when it reports results on November 12 (estimated) for the period ending September 30 2024
LSEG's mean analyst estimate for Microbot Medical Inc is for a loss of 17 cents per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Microbot Medical Inc is $7.00, above its last closing price of $0.94.
This summary was machine generated November 8 at 22:53 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments